Literature DB >> 20095225

Plasma concentrations, behavioural and physiological effects following intravenous and intramuscular detomidine in horses.

K R Mama1, K Grimsrud, T Snell, S Stanley.   

Abstract

REASONS FOR PERFORMING STUDY: Detomidine hydrochloride is used to provide sedation, muscle relaxation and analgesia in horses, but a lack of information pertaining to plasma concentration has limited the ability to correlate drug concentration with effect.
OBJECTIVES: To build on previous information and assess detomidine for i.v. and i.m. use in horses by simultaneously assessing plasma drug concentrations, physiological parameters and behavioural characteristics. HYPOTHESIS: Systemic effects would be seen following i.m. and i.v. detomidine administration and these effects would be positively correlated with plasma drug concentrations.
METHODS: Behavioural (e.g. head position) and physiological (e.g. heart rate) responses were recorded at fixed time points from 4 min to 24 h after i.m. or i.v. detomidine (30 microg/kg bwt) administration to 8 horses. Route of administration was assigned using a balanced crossover design. Blood was sampled at predetermined time points from 0.5 min to 48 h post administration for subsequent detomidine concentration measurements using liquid chromatography-mass spectrometry. Data were summarised as mean +/- s.d. for subsequent analysis of variance for repeated measures.
RESULTS: Plasma detomidine concentration peaked earlier (1.5 min vs. 1.5 h) and was significantly higher (105.4 +/- 71.6 ng/ml vs. 6.9 +/- 1.4 ng/ml) after i.v. vs. i.m. administration. Physiological and behavioural changes were of a greater magnitude and observed at earlier time points for i.v. vs. i.m. groups. For example, head position decreased from an average of 116 cm in both groups to a low value 35 +/- 23 cm from the ground 10 min following i.v. detomidine and to 64 +/- 24 cm 60 min after i.m. detomidine. Changes in heart rate followed a similar pattern; low value of 17 beats/min 10 min after i.v. administration and 29 beats/min 30 min after i.m. administration.
CONCLUSIONS: Plasma drug concentration and measured effects were correlated positively and varied with route of administration following a single dose of detomidine. POTENTIAL RELEVANCE: Results support a significant influence of route of administration on desirable and undesirable drug effects that influence case management.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20095225     DOI: 10.2746/042516409x421624

Source DB:  PubMed          Journal:  Equine Vet J        ISSN: 0425-1644            Impact factor:   2.888


  5 in total

1.  Anesthesia techniques used for field castration of 10 intractable horses.

Authors:  Bruce C Stover; Nigel A Caulkett
Journal:  Can Vet J       Date:  2021-05       Impact factor: 1.008

2.  Pharmacokinetic and pharmacodynamic analysis comparing diverse effects of detomidine, medetomidine, and dexmedetomidine in the horse: a population analysis.

Authors:  K N Grimsrud; S Ait-Oudhia; B P Durbin-Johnson; D M Rocke; K R Mama; M L Rezende; S D Stanley; W J Jusko
Journal:  J Vet Pharmacol Ther       Date:  2014-07-29       Impact factor: 1.786

3.  Effects of vatinoxan on cardiorespiratory function and gastrointestinal motility during constant-rate medetomidine infusion in standing horses.

Authors:  H Tapio; M R Raekallio; A Mykkänen; S Männikkö; M Scheinin; R C Bennett; O Vainio
Journal:  Equine Vet J       Date:  2019-03-14       Impact factor: 2.888

Review 4.  Practical Fluid Therapy and Treatment Modalities for Field Conditions for Horses and Foals with Gastrointestinal Problems.

Authors:  C Langdon Fielding
Journal:  Vet Clin North Am Equine Pract       Date:  2018-04       Impact factor: 1.792

5.  Development, Validation, and Reliability of a Sedation Scale in Horses (EquiSed).

Authors:  Alice Rodrigues de Oliveira; Miguel Gozalo-Marcilla; Simone Katja Ringer; Stijn Schauvliege; Mariana Werneck Fonseca; Pedro Henrique Esteves Trindade; José Nicolau Prospero Puoli Filho; Stelio Pacca Loureiro Luna
Journal:  Front Vet Sci       Date:  2021-02-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.